For patients with ACS undergoing DES implantation, de-escalating DAPT to P2Y12 inhibitor monotherapy is associated with lower bleeding risk.

De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary percutaneous coronary intervention may benefit stable patients with a lower BMI.

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

We know from TWILIGHT that ticagrelor monotherapy after an initial 3 months of DAPT also seems to be an acceptable strategy. However, in the THEMIS-PCI trial comparing aspirin/ticagrelor with ...

The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...

BMI Shapes DAPT De-escalation After Primary PCI De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary percutaneous coronary ...

The filing was based on results from the phase 3 THALES trial, which showed aspirin plus Brilinta 90 mg used twice daily for 30 days resulted in a statistically significant and clinically ...

“Our findings suggest that de-escalating DAPT to ticagrelor monotherapy will reduce aspirin-associated major bleeding while preserving the anti-ischemic benefits of antiplatelet therapy for ...